NCT04201951View on ClinicalTrials.gov

Tranexamic Acid for the Prevention of Blood Loss in High Risk Delivered Women

NACompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

October 10, 2020

Study Completion Date

October 10, 2020

Conditions
Postpartum HemorrhageHigh Risk PregnancyTranexamic AcidThird-Stage Postpartum Hemorrhage, With Delivery
Interventions
DRUG

Tranexamic acid injection

Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

OTHER

Glucose water 5%

Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

Trial Locations (2)

44001

Kurdistan Board for Medical speciality, Erbil

Maternity Teaching Hospital, Erbil

All Listed Sponsors
lead

Hawler Medical University

OTHER

NCT04201951 - Tranexamic Acid for the Prevention of Blood Loss in High Risk Delivered Women | Biotech Hunter | Biotech Hunter